Update shared on 27 Nov 2025
Fair value Decreased 3.14%Analysts have revised Zealand Pharma's price target downward from $818.80 to $793.06. This adjustment primarily reflects reduced growth expectations and a slightly higher discount rate in their updated models.
What's in the News
- Zealand Pharma A/S (CPSE:ZEAL) was dropped from the FTSE All-World Index (USD) (Key Developments)
Valuation Changes
- The consensus analyst price target has decreased from DKK 818.80 to DKK 793.06.
- The discount rate has risen slightly from 4.92% to 5.15%.
- The revenue growth forecast has improved, with the decline reducing from -36.67% to -33.64%.
- The net profit margin has fallen from 30.21% to 26.50%.
- The future P/E ratio has decreased from 93.32x to 89.76x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.